A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
This clinical trial evaluated the safety, efficacy, and pharmacokinetics of GSK1278863, a novel treatment for anemia associated with chronic kidney disease, in hemodialysis-dependent subjects. The study involved switching patients from a stable dose of recombinant human erythropoietin (rhEPO) to GSK1278863 over a four-week period.
Indication: Anaemia
Modality: small molecule
Target: GSK1278863 for anemia in hemodialysis-dependent patients
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Nov 14, 2017
Ingested: May 30, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: GSK1278863 for anemia in hemodialysis-dependent patients
View original source fields
Condition raw: Anaemia
Condition normalized: Anaemia
Modality raw: Anaemia
Modality normalized: small molecule
Target raw: GSK1278863 for anemia in hemodialysis-dependent patients
Target normalized: GSK1278863 for anemia in hemodialysis-dependent patients